Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Authors:
- Emad Uddin SajidESEmad Uddin Sajid
- Muhammad Hasnain AzeemMAMuhammad Hasnain Azeem
- Alishba FatimaAFAlishba Fatima
- Syeda Masooma JafriSJSyeda Masooma Jafri
- Danish HassanDHDanish Hassan
- Taha IbrahimTITaha Ibrahim
- Kashish Zehra ManjeeKMKashish Zehra Manjee
- Syed Rayyan AhmedSASyed Rayyan Ahmed
- Tooba AliTATooba Ali
- Rida ShakeelRSRida Shakeel
- Muhammad UsmanMUMuhammad Usman
- Raghabendra Kumar MahatoRMRaghabendra Kumar Mahato
Open Access
- 15 June 2026
- journal article
- review article
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Abstract
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.Keywords
This publication has 42 references indexed in Scilit:
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementEuropean Heart Journal, 2015
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trialsAtherosclerosis, 2012
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin TherapyJAMA, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease RiskJACC, 2009
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) TrialMayo Clinic Proceedings, 2005
- EzetimibeClinical Pharmacokinetics, 2005
- A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemiaClinical Therapeutics, 2004
- Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary HypercholesterolemiaCirculation, 2003